Does Telehealth Semaglutide or Tirzepatide Work? What Real-World Data Show

Can you get the same results from an online GLP-1 prescription as people did in the clinical trials? The 2026 data say yes, if you stay on it. Patients who kept up treatment through US, UK and Australian telehealth services lost 16–23% of their body weight, close to the 15% seen with Wegovy in STEP 1 and the 21% seen with Zepbound in SURMOUNT-1.^{[1][2][3][10][11]} The catch is how few people stay on. In one German online service, 88% had dropped out by 12 months, and averaged across everyone who started, weight loss was as low as 2.4%.^[4] This article covers what the real-world studies found, why so many people stop, and what that means when you choose a provider.

The short answer

• For people who stay on treatment, online care matches the trials. Weight loss among patients with follow-up was 16.6% at 68 weeks on semaglutide in the US, and 17.4% (UK) to 22.7% (Australia) at 12 months on tirzepatide.^[1][2][3]
• Most people don't stay on. Only 31.7% of Australian tirzepatide patients met the program's adherence criteria at 6 months, and 16.1% at 12 months. In Germany, 88% of semaglutide patients left within a year.^[3][4]
• This isn't only a telehealth problem. In a Danish general practice, 38% had permanently stopped semaglutide by 12 months.^[8] In an Ohio and Florida health system, average one-year weight loss was 5.9% when the drug was prescribed for obesity.^[7]
• Cost and pauses predict dropout. Chatbots don't fix it. In one online program, higher program cost and pausing treatment each roughly doubled or more the odds of dropping out, and adding an AI assistant did not improve adherence.^[5]

The trial benchmark

The numbers people expect come from two trials. In STEP 1, adults without diabetes taking semaglutide 2.4 mg lost 14.9% of their body weight at 68 weeks, compared with 2.4% on placebo.^[10] In SURMOUNT-1, tirzepatide 15 mg produced 20.9% at 72 weeks, compared with 3.1% on placebo.^[11] STEP 1 paired the drug with a lifestyle intervention.^[10] Real-world results are often lower, and the studies below show that stopping treatment is a big part of why.

What the telehealth studies found

Read the “who it counts” column first. The impressive numbers come from people who stayed in the program and kept logging weights. In the Ro study, only 655 of the 4,500 sampled patients had a weight recorded within two weeks of week 68, so the 16.6% describes roughly one in seven starters.^[1] The German study is the only one that reports what happened to everyone who started. Counting dropouts as having lost nothing, average loss was 2.40%, against 15.13% for the 12% who stayed fully engaged. The authors concluded that “real-world success is strictly conditional upon long-term persistence.”^[4] The one study with academic authors, a single-arm US program that paired telemedicine prescribing with a behavioral course, reported 12.3% weight loss at 24 weeks with last observations carried forward for dropouts.^[6]

Safety looked like the trials. In the Ro cohort, the most common side effects were nausea or vomiting (37.3%) and constipation (15.6%), with “no new safety signals.”^[1] In Australia, side effects were “common but mostly mild/moderate” and did not predict who dropped out.^[3]

Is in-person care any better?

The best clinic-based comparisons show the same pattern. In a large Ohio and Florida health system, adults started on semaglutide or liraglutide between 2015 and 2022 lost a mean 5.9% at one year when the drug was prescribed for obesity. People who kept their prescription going with gaps of under 90 days lost 5.5%, against 1.8% for those covered for fewer than 90 days. Persistent coverage more than tripled the odds of losing 10% or more.^[7] Those results are lower than the telehealth figures partly because they count everyone who started, and partly because about half the cohort was on liraglutide, which produced less than half the weight loss of semaglutide in the same study (−2.2% vs −5.1%).

In a Danish general practice, 38% of people had permanently stopped semaglutide by 12 months and another 15% had paused it. The 48% still on treatment had lost 13.6%, and 40% of them were on 1.0 mg or less, well below the 2.4 mg target dose.^[8] Stopping early and staying on lower doses happens everywhere, not just online.

Why people stop, according to the data

• Cost. In a 6-month analysis of an online obesity program, higher program cost was associated with 2.46 times the odds of dropping out, and pausing the program with 2.51 times the odds.^[5] In the UK, when tirzepatide's price rose for self-paying patients, new semaglutide starts jumped by 31 percentage points within a month.^[9]
• Complexity. In Germany, people with three or more health conditions were more than twice as likely to drop out (odds ratio 2.12), and people who had used a GLP-1 before were also more likely to leave.^[4]
• Early results set expectations. In Australia, weight lost in the first month was the strongest predictor of results at 6 and 12 months. The authors call for ways “to manage early weight-loss expectations.”^[3] If the first weeks feel slow, see the first 30 days on a GLP-1.
• Very heavy tracking was a warning sign, not a strength. Tracking more than 25 times in the first month was linked to much higher dropout (odds ratio 15.8), while moderate, steady engagement predicted staying on.^[5] The Australian study saw the same “paradox.”^[3]

Adding an AI chatbot did not help. After one program introduced an AI assistant, 6-month adherence rose from 47.3% to 53.2%, but once other factors were accounted for, the period after the chatbot was linked to higher odds of dropping out. The authors concluded that providers should prioritize “proactive behavioural risk screening and financial accessibility over baseline AI integration.”^[5]

Do you need the highest dose?

Often not. In the UK cohort, “clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses,” and 89.9% of patients with a 6-month weight had lost at least 5%. More regular ordering, meaning fewer gaps, went with more weight loss.^[2] That fits the Danish finding that many people do well below the label's target dose.^[8] For a structured approach to lower doses once you reach a goal, see GLP-1 maintenance and step-down dosing.

What this means when choosing an online provider

The studies point to a few things that matter more than a provider's marketing:

1. A price you can sustain for a year or more. Cost was one of the strongest predictors of dropping out.^[5] Compare total monthly cost, including any membership fee, using our GLP-1 price transparency index.
2. Flexible dosing. Providers that let you stay on a dose that works, rather than forcing escalation, match how people actually do well.^[2][8]
3. Real clinician follow-up. In Australia, ongoing health-coach messaging and weekly weight tracking were “strongly associated with both retention and greater weight loss.”^[3]
4. Easy pausing and cancellation terms you understand up front. Pauses predicted dropout, so know what happens to your price and dose if you need a break. Our telehealth cancellation index compares each service's terms.

For why people stop in general, see why people quit Ozempic. For what happens to the weight afterward, see rebound weight gain after stopping.

Bottom line

Telehealth is not a weaker way to get a GLP-1. When people stay on treatment, online prescribing produces weight loss in the same range as the pivotal trials, with similar side effects. The weak point is persistence. Most people who start through an online service, like most who start through a clinic, are off the drug within a year, and the averages fall sharply when they are counted. Choose a provider on sustainable price, dose flexibility and follow-up, and plan for treatment that lasts longer than a few months.